A Phase 3 Randomized Double-blind Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC (KEYNOTE-992)
Brief description of study
The purpose of the study is to determine the safety and efficacy of Pembrolizumab (MK-3475) and Chemoradiotherapy (CRT) for people who have muscle-invasive bladder cancer. We want to know if Pembrolizumab (MK-3475) and Chemoradiotherapy (CRT) is better than CRT alone. You will be randomized to either treatment.
Clinical Study Identifier: s19-01027
ClinicalTrials.gov Identifier: NCT04241185
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
